Research Square

Preprints are preliminary reports that have not undergone peer review.
They should not be considered conclusive, used to inform clinical practice,
or referenced by the media as validated information.

Impaired Fetal Growth Mediates the Association Between Hypertensive Disorders of Pregnancy and Neurodevelopment in Extremely Preterm Infants

Shipra Jain

shipra.jain@cchmc.org

Cincinnati Children's Hospital Medical Center https://orcid.org/0009-0002-5586-4570

Shampa Saha

RTI international https://orcid.org/0000-0002-8305-3495

Maria Barnes-Davis

Cincinnati Children's Hospital Medical Center https://orcid.org/0000-0001-5760-740X

Susan Hintz

Stanford University https://orcid.org/0000-0001-7023-4433

Krisa Van Meurs

Stanford University School of Medicine and Lucile Packard Children' https://orcid.org/0000-0002-9242-1480

Tanya Cahill

CCHMC

Stephanie Merhar

U Cincinnati and Cincinnati Children's Hospital Medical Center https://orcid.org/0000-0002-3331-4220

Article

Keywords: extremely preterm infants, hypertensive disorders of pregnancy, cognitive development, infant neurodevelopment, birth weight Z-scores

Posted Date: November 10th, 2026

DOI: https://doi.org/10.21203/rs.3.rs-11432518/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License

Additional Declarations: There is **NO** conflict of interest to disclose.

Abstract

Objective: To evaluate the association between hypertensive disorders of pregnancy (HDP) and neurodevelopmental outcomes in extremely preterm (EPT) infants and determine whether fetal growth mediates this relationship.

Study Design: Retrospective multicenter cohort study of infants born at 22 $^{0}/_{7}$–26 $^{6}/_{7}$ weeks' gestation within the NICHD Neonatal Research Network (2012–2019). HDP was defined as maternal hypertension before/during pregnancy. Primary outcome was Bayley-3 cognitive composite score at 22–26 months corrected age; secondary outcomes included language, motor, and composite death/neurodevelopmental impairment (NDI). Multivariable regression adjusted for maternal, perinatal, and socioeconomic confounders. Mediation analyses evaluated mediating role of birth weight Z-scores and gestational age.

Results: Among 4,712 infants, 1,178 (25%) were HDP-exposed. HDP exposure was associated with lower cognitive, language, and motor scores, and higher odds of death/NDI. Birth weight Z-scores mediated ~65% of this relationship.

Conclusions: HDP exposure was associated with adverse neurodevelopment in EPT infants, largely mediated through impaired fetal growth.

Introduction:

Hypertensive disorders of pregnancy (HDP), including gestational and chronic hypertension, affect 25–50% of extremely preterm (EPT) deliveries,[1,2] with increasing rates in the United States.[3] Both forms can progress to severe conditions such as pre-eclampsia and eclampsia, negatively impacting maternal health[1] and contributing to adverse neonatal outcomes such as premature birth,[4] intrauterine growth restriction,[5,6] and long-term metabolic problems.[7,8]

HDP represents a spectrum of placental vascular disorders characterized by abnormal spiral artery remodeling, impaired uteroplacental perfusion, oxidative stress, endothelial dysfunction, and chronic fetal hypoxemia.[9] Preclinical studies suggest that intrauterine HDP exposure can hinder fetal brain development,[10–14] through placental insufficiency,[15] triggering an inflammatory cascade and nutrient deficiency that impairs fetal growth, disrupts fetal programming,[10–12] leading to epigenetic changes that affect brain development and cause white matter[16,17] and cerebrovascular injury.[18] Together, these mechanisms may contribute to impaired neurodevelopment resulting in cognitive, language, and motor delays, as evident in term infants.[19–21]

Human studies in term-born infants consistently report impaired neurodevelopment associated with HDP exposure.[21–24] However, findings in EPT infants are inconsistent. While some studies suggest poor outcomes,[22,25–28] many indicate better neurodevelopment in the exposed, suggesting a potential

neuroprotective effect of HDP.[29–33] Yet, many of these studies inappropriately controlled for intermediate factors such as fetal growth restriction and prematurity that lie in the causal pathway between maternal hypertension and later outcomes.[29,33–36] These intermediate variables partly account for the total effect, and their adjustment in analyses results in overadjustment that negates the total effect.[37,38]

An additional challenge in evaluating the association between HDP and neurodevelopment among EPT infants is the etiologic heterogeneity of EPT birth. HDP-associated EPT deliveries are frequently medically indicated, whereas unexposed EPT births more commonly result from spontaneous preterm labor, preterm rupture of membranes, or intrauterine inflammation, leading to a substantially higher prevalence of histologic chorioamnionitis in the unexposed group.[26,28,39] Because chorioamnionitis is independently associated with adverse neurodevelopmental outcomes,[39,40] a higher prevalence of chorioamnionitis in the unexposed group may contribute to worse neurodevelopmental outcomes in that group and potentially create or exaggerate an apparent neuroprotective association with HDP.[30,41,42] Accounting for chorioamnionitis is therefore important when estimating the association between HDP and neurodevelopment, particularly when interpreting previously reported associations suggesting better neurodevelopment among HDP-exposed EPT infants.[33,43]

The objective of our study was to evaluate the association between maternal HDP and neurodevelopment of EPT infants. We propose that birth weight is a key mediator in the causal pathway between HDP and infant neurodevelopmental outcomes, rather than a confounder. Additionally, factors such as chorioamnionitis and socioeconomic status,[44] which influence both exposure and outcomes, should be included as confounders.

Methodology:

Study Participants

We included EPT infants born at 22 0/7–26 6/7 weeks gestation between 7/1/2012 and 12/31/2019 who attended the NICHD Neonatal Research Network's 22–26-month follow-up visit. We excluded infants with major congenital anomalies that affected the central nervous system, congenital heart disorders, and chromosomal abnormalities. The Follow-up study was approved by the Institutional Review Board at each participating center.

Variable Definition

Trained research staff collected maternal and infant data during the birth hospitalization. We defined HDP exposure as maternal diagnosis of hypertension present before or during pregnancy, per obstetricians' clinical guidelines.[45] Antenatal corticosteroid and magnesium therapy were defined as receipt of any dose before delivery.[45] Histologic chorioamnionitis was defined as placental inflammatory infiltration on pathological examination by pathologists.[46] Maternal race and ethnicity were self-identified by the mother. Socioeconomic status was assessed using mother's health insurance status.

Neurodevelopmental Evaluation: We assessed neurodevelopment at 22–26 months corrected age (CA) using the 3rd edition of the Bayley Scales of Infant and Toddler Development (Bayley-3),[47] administered by certified examiners following reliability standards established by the NICHD NRN.[48] The Bayley-3 is a widely used standardized tool designed to assess development in children.[47] The primary outcome was the Bayley-3 cognitive composite score because experimental and human studies suggest that placental insufficiency, fetal hypoxia, inflammation, and impaired white matter maturation associated with HDP may particularly affect higher-order cortical development and later cognitive functioning.[10,11,26,28] Additionally, cognitive performance at 2 years CA is strongly associated with later educational and functional outcomes in EPT infants.[49] Secondary outcomes included language (a combination of expressive and receptive language scores), motor (including both fine and gross motor skills) composite scores, and a composite measure of neurodevelopmental impairment (NDI) and death. Deaths were included if they occurred during the hospitalization or before 2 years follow-up. NDI was defined as 1 or more of the following according to the latest NRN definition: Bayley-3 Cognitive Composite Score < 85, Bayley-3 Motor Composite Score < 85, cerebral palsy with Gross Motor Function Level ≥ 2,[50] bilateral blindness, or hearing impairment with or without amplification.[51] Analyses of Bayley-3 scores were restricted to surviving infants with available cognitive assessments at 22–26 months CA. Analyses evaluating the composite outcome of death/NDI included the entire eligible live-born cohort to minimize survivor bias and competing risk bias.

Statistical Analysis

Baseline patient characteristics were compared between HDP-exposed versus unexposed infants using t-tests or Wilcoxon rank sum tests for continuous variables and Chi-square for categorical variables.

Associations between HDP exposure and Bayley-3 scores or NDI/death were analyzed, adjusting for *a priori* covariates: histologic chorioamnionitis, antenatal steroids, antenatal magnesium sulfate, infant sex, multiple gestation, birth hospital, maternal age, maternal race, and mother's health insurance status. We used maternal health insurance as a proxy for socioeconomic status due to minimal missing data, whereas maternal education and household income did not differ significantly between groups. The β estimates and their 95% confidence intervals were obtained using generalized linear regression for continuous outcomes. Odds ratios are presented for the categorical binary outcome of NDI/death using logistic regression. Because mortality represents a competing outcome among EPT infants, separate analyses were performed for neurodevelopmental outcomes among survivors and for the composite outcome of death or NDI in the full eligible cohort. This approach was used to reduce survivor bias and better capture the overall burden associated with HDP exposure.

Confounders were selected *a priori* based on biologic plausibility and causal inference principles informed by directed acyclic graph methodology. Variables occurring downstream of HDP exposure, including gestational age, birth weight, interventricular hemorrhage (IVH), sepsis, severe bronchopulmonary dysplasia (BPD), necrotizing enterocolitis, and other neonatal morbidities, were considered potential mediators rather than confounders as they may lie in the pathway between HDP

and infant neurodevelopment, and therefore were excluded in adjusted models (Fig. 1) to avoid overadjustment bias.[37] Importantly, although histologic chorioamnionitis is unlikely to influence the occurrence of HDP and therefore may not represent a conventional confounder, it was intentionally included as an a priori covariate because of its marked imbalance between groups and its established association with neurodevelopmental outcomes in EPT infants.[39] Antenatal corticosteroid and magnesium sulfate exposures were included as prespecified covariates because their administration may differ according to the obstetric circumstances leading to EPT delivery and both have established associations with neonatal and neurodevelopmental outcomes. Antenatal magnesium sulfate was additionally considered relevant because it may be administered either for fetal neuroprotection or in the management of severe hypertensive disease. Gestational diabetes mellitus (GDM) was not included in the adjusted models because data were available only from 2016 onward, resulting in substantial missingness. Additionally, routine GDM screening typically occurs at 24–28 weeks' gestation, potentially limiting ascertainment among EPT pregnancies.

We specifically evaluated the mediating roles of gestational age and fetal growth restriction on the association between HDP and neurodevelopment using mediation analyses with the SAS 9.4 CAUSALMED procedure. Separate models assessed the indirect effects of HDP through gestational age at birth and birth weight Fenton Z-scores[52] while distinguishing these from direct effects of HDP on Bayley-3 outcomes. Outcome and mediator models were adjusted for a priori confounders, and 95% confidence intervals were estimated using 1000 bootstrap iterations. Further, given the heterogeneity of HDP, we conducted a sensitivity analysis restricted to pregnancies complicated by pre-existing maternal hypertension. Additional methodological details are provided in Supplement 1.

Results:

Of 8574 EPT infants born at NRN centers between 07/1/2012 and 12/31/2019, 331 met exclusion criteria, 19 were ineligible for follow-up (not born at NRN hospitals or not enrolled in NRN study), and 2590 died before the 22-26 months assessment. Among surviving eligible infants, 909 lacked Bayley-3 cognitive data, including 668 lost to follow-up. Ultimately, 4712 infants with complete Bayley-3 cognitive outcomes were included, of whom 1178 (25%) were HDP-exposed and 3534 were unexposed (Figure 2).

Infants with and without HDP exposure differed in maternal age, race, antenatal magnesium exposure, histologic chorioamnionitis, GDM, primary language, outborn status (defined as if the infant was born at an outside hospital other than the study center and needed transfer), multiple gestation, gestational age, birth weight, infant sex, IVH, and severe BPD (Table 1). Infants with and without follow-up differed in maternal age, race, education, birth hospital, gestational age, and birth weight (Table 2). Neurodevelopmental outcomes were significantly worse among HDP-exposed infants than unexposed infants (Table 3).

In both unadjusted and adjusted models, HDP exposure was associated with lower Bayley-3 cognitive, language, and motor composite scores (Table 4). After adjustment, HDP-exposed infants scored 2.44

points lower on the cognitive (95% CI: -3.57 to -1.32, p < 0.01), 2.80 points lower on the language (95% CI: -4.13 to -1.46, p < 0.01), and 2.91 points lower on the motor (95% CI: -4.18 to -1.64, p < 0.01) composites. The odds of NDI/death were 1.23 times higher in the HDP-exposed group (Table 4).

Mediation analysis demonstrated that the association between HDP and cognitive outcomes was largely mediated through impaired fetal growth, as measured by birth weight Fenton Z-scores. The direct effect of HDP was not significant, whereas the indirect effect through birth weight Z-score was highly significant (p<0.01), accounting for 64.6% of the total effect. Similar findings were observed for language and motor outcomes (Figure 3, Table 5).

We also evaluated gestational age as a potential mediator of the association between HDP and Bayley-3 outcomes (Supplementary Table 1). Mediation analysis demonstrated a suppression effect, with direct and indirect effects in opposite directions, likely reflecting methodological artifact rather than a true biologic effect. This finding may relate to the restricted cohort of live-born EPT infants, where unexposed infants were born at earlier gestational ages (i.e., 24 weeks) than HDP-exposed infants (i.e., 25 weeks). Because longer gestation is neuroprotective in EPT infants, gestational age could not be fully evaluated as a mediator across the full spectrum of HDP-exposed pregnancies. These findings should therefore be interpreted cautiously.

In a sensitivity analysis restricted to infants exposed to pre-existing/chronic maternal hypertension, the results remained similar (Supplement Table 2).

Comment:

In our multisite prospective study involving 4712 EPT infants born at < 27 weeks gestation, HDP exposure was significantly associated with worse cognitive, motor, and language outcomes at two years CA. This relationship was largely mediated by HDP's impact on in-utero growth, accounting for approximately 65% of the total effect, supporting a potential role of placental dysfunction and impaired fetal growth in neurodevelopmental vulnerability.

Our study showed that HDP exposure was associated with a 2- to 3-point reduction in Bayley-3 scores (~ 20% SD), which, while modest, could be clinically relevant. Although the effect size is relatively small at the individual level, even subtle early developmental differences can accumulate over time, especially in the absence of interventions, potentially impacting school readiness, executive functioning, and future academic success, particularly among EPT infants already at high neurodevelopmental risk. Identifying these differences early enables tailored interventions, such as early speech therapy, occupational therapy, or enriched learning environments, that can enhance long-term educational, behavioral, and health outcomes.

The mechanisms linking maternal-placental health and fetal neurodevelopment remain incompletely understood. HDP may impair placental perfusion, causing hypoxia, ischemia, inflammation, and nutrient restriction,[53] which may disrupt fetal neurogenesis, contributing to cortical gliosis, white matter lesions,

decreased Purkinje fibers, increased apoptosis of pre-oligodendrocytes, and hypomyelination, observed in animal models, ultimately culminating in adverse neurodevelopmental outcomes.[10–14]

However, evidence on HDP's impact on preterm infants' neurodevelopment is inconsistent, with studies reporting no association,[34,54] adverse outcomes,[22,25–28] or even apparent neuroprotection.[29–33] This variability may reflect inappropriate comparison groups, particularly those consisting of other high-risk preterm infants with significant comorbidities, such as chorioamnionitis, a leading cause of preterm births.[30,41,42] Acute chorioamnionitis is associated with impaired brain development[39] and long-term neurodevelopmental deficits in preterm infants.[40] In our cohort, histologic chorioamnionitis was more than twice as common among unexposed infants (68% vs 29%), suggesting inadequate adjustment for chorioamnionitis in prior studies may have biased findings toward a perceived neuroprotective effect of HDP. Studies adequately controlling for chorioamnionitis, including ours, consistently report associations between HDP exposure, abnormal brain maturation, and neurodevelopmental delay.[26,28]

Inconsistent findings may also reflect overadjustment in prior studies, particularly for gestational age and markers of fetal growth restriction such as birth weight or small-for-gestational-age status.[29,33–35] These covariates function as mediators rather than confounders, as they lie on the causal pathway between maternal HDP and infant neurodevelopment (Fig. 1).[37] Adjusting for these mediators in multivariable models can obscure the true impact of HDP by artificially diminishing group differences and thus masking HDP's role as a neurodevelopmental risk factor.[38] Nakamura et al. reported that adjustment for birth weight substantially reduced the observed association between HDP and neurodevelopmental outcomes at 3 years of age.[29]

We conducted mediation analyses to better delineate the mechanisms through which HDP impacts neurodevelopment. Mediation analyses allow us to separate HDP's direct effects on the developing brain, such as those stemming from placental ischemia, hypoxia, and inflammation, from its indirect effects, which occur through pathways involving nutrient restriction and impaired fetal growth. We demonstrated that impaired fetal growth, attributable to HDP exposure, mediated approximately 65% of the total effect on cognitive, motor, and language outcomes at two years CA, underscoring that intrauterine growth restriction is a critical intermediary through which HDP exerts its influence on early brain development, emphasizing that growth restriction is a mediator rather than a confounder. Similarly, our prior work demonstrated that birth weight Z-score mediated approximately 22% of the association between HDP and structural brain abnormalities on term-equivalent MRI in preterm infants.[28] Together, these findings highlight that mediation analysis is instrumental in distinguishing between HDP's direct neurotoxic effects and its secondary impact via impaired fetal growth. By clarifying these distinct pathways, our results add important insight into HDP's multifaceted impact on neurodevelopment in EPT infants.

Interestingly, HDP-exposed infants had lower rates of severe IVH despite worse neurodevelopmental outcomes, suggesting mechanisms beyond overt hemorrhagic injury contribute to impaired brain

development following HDP exposure. Experimental and neuroimaging studies implicate chronic placental insufficiency, fetal hypoxia, inflammation, impaired cerebral perfusion, and disrupted white matter maturation as potential pathways even without severe IVH.[26] Similarly, our prior work demonstrated that term-equivalent

MRI abnormalities partially mediated the association between HDP exposure and adverse neurodevelopment at 2 years CA.[28] Together, these findings support that HDP-related neurodevelopmental vulnerability may arise from disrupted fetal brain maturation secondary to HDP-associated placenta dysfunction.

We also examined the potential mediating role of gestational age between HDP exposure and neurodevelopmental outcomes. Gestational age operated as a suppressor rather than a mediator, reducing the total effect by 22% (Supplementary Table 1).[55] This likely reflects a methodological artifact rather than a true causal relationship, as there is no evidence suggesting HDP is associated with increased gestational age and is primarily driven by the younger gestational age of unexposed infants (mean of 24 weeks) compared with HDP-exposed infants (mean of 25 weeks; see Table 1). Further, because our cohort was restricted to live-born EPT infants, gestational age could not be fully evaluated as a mediator; therefore, these findings should be interpreted with caution.

Strengths and Limitations:

Our study examined the neurodevelopmental effects of HDP in over 4700 EPT infants born before 27 weeks' gestation, allowing a comprehensive analysis with robust statistical power to detect meaningful associations. We rigorously controlled for significant confounders, particularly histologic chorioamnionitis, an important condition associated with adverse neurodevelopmental outcomes in preterm infants and a potential bias if left uncontrolled. Placental pathology was available for 95% of the cohort. We employed advanced statistical methods, specifically mediation analysis, which allowed us to differentiate the direct impact of HDP on neurodevelopment from its indirect effects via in utero growth restriction and prematurity. This approach helps clarify the causal pathway and the specific mechanisms through which HDP affects preterm infant development.

However, the retrospective design introduces potential selection bias and residual confounding, despite adjusting for known confounders. The NRN database lacked information on HDP timing, severity, and subtype, precluding assessment of differential effects of HDP phenotype. Approximately 16% of infants were lost to follow-up, potentially introducing attrition bias despite adjustment for baseline antenatal differences. Survivor bias is another consideration, as severe HDP may increase fetal and neonatal mortality, potentially underestimating adverse effects among survivors. Although we evaluated the composite outcome of death or NDI, stillbirths and fetal deaths were unavailable. Future studies using fetus-at-risk or competing-risk approaches are needed to better characterize the total impact of HDP on offspring outcomes. Further, adjustment for histologic chorioamnionitis cannot fully account for the distinct obstetric pathways leading to EPT birth among HDP-exposed and unexposed pregnancies, and

residual confounding related to these underlying phenotypes remains possible. Finally, while our findings provide valuable insights, the study's generalizability may be limited to EPT infants, and results may not apply to infants born closer to term.

Conclusion:

Our findings underscore that HDP is an independent risk factor for adverse neurodevelopmental outcomes in EPT infants, affecting cognitive, language, and motor skills at two years CA. Much of this effect is mediated by HDP's impact on fetal growth, highlighting intrauterine growth restriction as a significant pathway through which HDP influences early brain development. While the study addresses a major gap in understanding HDP's role in preterm infant neurodevelopment, future research should investigate specific HDP subtypes and their severity, consider additional confounders, and aim for prospective, longitudinal studies to further elucidate HDP's mechanisms. Comprehensive prenatal care aimed at managing HDP and mitigating its effects could potentially improve neurodevelopmental outcomes for at-risk infants. Furthermore, infants exposed to HDP should receive consistent follow-up in NICU high-risk clinics, with early intervention strategies to support long-term development.

Abbreviations

EPT
extremely preterm
HDP
hypertensive disorders of pregnancy
SD
standard deviation
IQR
interquartile range

Declarations

Conflict of Interest Disclosures:

None of the authors have any conflicts of interest to disclose. The funders played no role in the design, analysis, or presentation of the findings.

Prior Presentation

Presented as a platform presentation at the 2024 Pediatric Academic Societies Meeting, Toronto, Canada.

Role of Funder

The NIH had no role in the design and conduct of the study.

Hypertensive disorders of pregnancy

Cognitive scores on Bayey-3 at 2 years corrected age

Direct Effect

Funding

Support: The National Institutes of Health and the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) (U10 HD27871, U10 HD53119, UG1 HD21364, UG1 HD21373, UG1 HD21385, UG1 HD27851, UG1 HD27853, UG1 HD27856, UG1 HD27880,UG1 HD27904, UG1 HD34216, UG1 HD36790, UG1 HD40492, UG1 HD40689, UG1 HD53089, UG1 HD53109, UG1 HD68244, UG1 HD68270, UG1 HD68278, UG1 HD68263, UG1 HD68284, UG1 HD87226, UG1 HD87229) and the National Center for Advancing Translational Sciences (NCATS) (UL1 TR6, UL1 TR41, UL1 TR42, UL1 TR77, UL1 TR93, UL1 TR442, UL1 TR454, UL1 TR1117) provided grant support through cooperative agreements for the Neonatal Research Network. NICHD staff provided input into the study design, conduct, analysis, and manuscript drafting; NCRR and NCATS cooperative agreements provided infrastructure support to the NRN.

Acknowledgements

The National Institutes of Health, the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD), the National Center for Research Resources (NCRR), and the National Center for Advancing Translational Sciences (NCATS) provided grant support for the Neonatal Research Network's Generic Database and Follow-up through cooperative agreements. While NICHD staff had input into the study design, conduct, analysis, and manuscript drafting, the comments and views of the authors do not necessarily represent the views of NICHD, the National Institutes of Health, the Department of Health and Human Services, or the U.S. Government.

Participating NRN sites collected data and transmitted it to RTI International, the data coordinating center (DCC) for the network, which stored, managed and analyzed the data for this study. On behalf of the NRN, RTI International had full access to all of the data in the study, and with the NRN Center Principal Investigators, takes responsibility for the integrity of the data and accuracy of the data analysis.

We are indebted to our medical and nursing colleagues and the infants and their parents who agreed to take part in this study. The following investigators, in addition to those listed as authors, participated in

this study:

NRN Steering Committee Chair: Richard A. Polin, MD, Division of Neonatology, College of Physicians and Surgeons, Columbia University, (2011–2023).

Alpert Medical School of Brown University and Women & Infants Hospital of Rhode Island (UG1 HD27904) – Abbot R. Laptook, MD; Martin Keszler, MD; Betty R. Vohr, MD; Angelita M. Hensman, PhD RNC-NIC; Elisa Vieira, BSN RN; Lucille St. Pierre, BS; Barbara Alksninis, RNC PNP; Andrea Knoll; Mary L. Keszler, MD; Teresa M. Leach, MEd CAES; Elisabeth C. McGowan, MD; Victoria E. Watson, MS CAS.

Case Western Reserve University, Rainbow Babies & Children's Hospital (UG1 HD21364) – Anna Maria Hibbs, MD MSCE; Michele C. Walsh, MD MS; Nancy S. Newman, RN; Deanne E. Wilson-Costello, MD; Bonnie S. Siner, RN; Elizabeth Roth, PhD.

Children’s Mercy Hospital (UG1 HD68284) – William E. Truog, MD; Eugenia K. Pallotto, MD MSCE; Howard W. Kilbride, MD; Cheri Gauldin, RN BS CCRC; Anne Holmes, RN MSN MBA-HCM CCRC; Kathy Johnson, RN CCRC; Allison Scott, RNC-NIC BSN CCRC; Prabhu S. Parimi, MD; Lisa Gaetano, RN MSN.

Cincinnati Children's Hospital Medical Center, University Hospital, and Good Samaritan Hospital (UG1 HD27853, UL1 TR77) – Brenda B. Poindexter, MD MS; Kurt Schibler, MD; Jae Kim, MD PhD; Cathy Grisby, BSN CCRC; Kristin Kirker, CRC; Sandra Wuertz, RN BSN CLC; Juanita Dudley, RN BSN; Julia Thompson, RN BSN; Lisa Henkes, RN BSN; Sara Stacey, BA; Devan Hayes, BS; Courtney Robinson, SLP; Greg Muthig, BA, David Russell, JD; Teresa Gratton, PA; Traci Beiersdorfer, RN BSN.

Duke University School of Medicine, University Hospital, University of North Carolina, Duke Regional Hospital, and WakeMed Health & Hospitals (UG1 HD40492, UL1 TR1117) – C. Michael Cotten, MD MHS; Ronald N. Goldberg, MD; William F. Malcolm, MD; Patricia L. Ashley, MD; Deesha Mago-Shah, MD; Mollie Warren, MD; Joanne Propst, RN JD; Kimberley A. Fisher, PhD FNP-BC IBCLC; Kathryn E. Gustafson, PhD; Matthew M. Laughon, MD MPH; Carl L. Bose, MD; Janice Bernhardt, MS RN; Gennie Bose, RN; Janice Wereszczak, CPNP-AC/PC; Andrea Trembath, MD MPH; Jennifer Talbert, MS RN; Stephen D. Kicklighter, MD; Alexandra Bentley, MD; Laura Edwards, MD; Ginger Rhodes-Ryan, ARNP MSN NNP-BC; Donna White, RN-BC BSN.

Emory University, Children’s Healthcare of Atlanta, Grady Memorial Hospital, and Emory University Hospital Midtown (UG1 HD27851, UL1 TR454) – Ravi M. Patel, MD MS; David P. Carlton, MD; Brenda B. Poindexter, MD MS; Nathalie L. Maitre, MD PhD; Ira Adams-Chapman, MD (deceased); Yvonne Loggins, RN; Diane Bottcher, RN; Sheena L. Carter, PhD; Salathiel Kendrick-Allwood, MD; Maureen Mulligan LaRossa, RN; Judith Laursen, RN; Colleen Mackie, RRT; Amy Sanders, PsyD; Gloria Smikle, PNP; Lynn Wineski, NNP.

Eunice Kennedy Shriver National Institute of Child Health and Human Development – Michele C. Walsh, MD MS; Andrew A. Bremer, MD PhD; Rosemary D. Higgins, MD; Stephanie Wilson Archer, MA.

Indiana University, University Hospital, Methodist Hospital, Riley Hospital for Children, and Wishard Health Services (UG1 HD27856, UL1 TR6) – Gregory M. Sokol, MD; Brenda B. Poindexter, MD MS; Lu-Ann Papile, MD; Heidi Harmon, MD MS; Dianne E. Herron, RN CCRC; Abbey C. Hines, PsyD; Carolyn Lytle, MD MPH; Lucy Smiley, CCRC; Leslie Dawn Wilson, BSN CCRC; Donna Watkins, MSN NNP-BC; Susan Gunn, NNP-BC CCRC; Jeff Joyce, CCRC (deceased).

McGovern Medical School at The University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, and Memorial Hermann Southwest Hospital (U10 HD21373, UG1 HD87229) – Jon E. Tyson, MD MPH; Amir M. Khan, MD; Kathleen A. Kennedy, MD MPH; Barbara J. Stoll, MD; Ricardo A. Mosquera, MD MS; Andrea F. Duncan, MD MS; Nora I. Alaniz, BS; Elizabeth Allain, PhD; Julie Arldt-McAlister, MSN APRN; Fatima Boricha, MD; Allison G. Dempsey, PhD; Elizabeth Eason, MD; Carmen Garcia, RN BSN; Donna J. Hall, RN; Janice John, CPNP; Karen Martin, RN; Georgia E. McDavid, RN; Shannon L. McKee, EdS; Kimberly Rennie, PhD; Tina Reddy, MD; Debasree Sana Boral, BS IMG; Daniel K. Sperry, RN; Emily Stephens, BSN RNC-NIC; Michelle White, BSN RNC-NIC; Sharon L. Wright, MT (ASCP), Dinorah Zanger, PhD.

Nationwide Children’s Hospital, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Center for Perinatal Research, The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center,, and Riverside Methodist Hospital (UG1 HD68278) – Pablo J. Sánchez, MD; Leif D. Nelin, MD; Jonathan L. Slaughter, MD MPH; Sudarshan R. Jadcherla, MD; Nathalie L. Maitre, MD PhD; Christopher Timan, MD; Omid Fathi, MD; Keith O. Yeates, MD PhD; Patricia Luzader, RN; Julie Gutentag, RN BSN; Jennifer L. Grothause, BA RN BSN; Melanie Stein, RRT BBS; Rox Ann Sullivan, RN BSN; Cole D. Hague, BA MS; Helen Carey, PT DHSc PCS; Michelle Chao, BS; Stephanie Burkhardt, BS MPH; Margaret Sullivan, BS; Lina Yossef-Salameh, MD; Mary Ann Nelin, MD; Erna Clark, BA; Julie C. Shadd, BSN RD; Courtney Park, RN BSN; Courtney Cira, BS; Erin Fearns; Kristi Small, BS; Sarah A. Keim, PhD MA MS; Christine A. Fortney, RN PhD; Aubrey Fowler, BS, Jacqueline McCool; Lindsay Pietruszewski, PT DPT; Jessica Purnell, BS CCRC; Kyrstin Warnimont, BS; Laura Marzec, MD; Bethany Miller, RN BSN; Demi R. Beckford, MHS; Hallie Baugher, BS MSN; Julia Newton, MPH; Katelyn Levengood, PT DPT; Nancy Batterson, OT/L; Brittany DeSantis, BS.

RTI International (UG1 HD36790) – Abhik Das, PhD; Carla M. Bann, PhD; Jeanette O’Donnell Auman, BS; Margaret M. Crawford, BS; Jenna Gabrio, BS MPH; Jamie E. Newman, PhD MPH; Lindsay Parlberg, BS; Carolyn M. Petrie Huitema, MS; Kristin M. Zaterka-Baxter, RN BSN; David C. Leblond, BS; Anna Mazur, BA; Annie M. Bayard, BS; Amanda Lewis.

Stanford University, El Camino Hospital, and Lucile Packard Children's Hospital (UG1 HD27880, UL1 TR93) – Valerie Y. Chock, MD MS Epi; David K. Stevenson, MD; M. Bethany Ball, BS CCRC; Marian M. Adams, MD; Alexis S. Davis, MD MS Epi; Dona Bahmani, CRC; Barbara Recine, MA; Lilia Rutkowska, MA; Barbara Bentley, PsychD MSEd; Maria Elena DeAnda, PhD; Anne M. DeBattista, RN PNP PhD; Beth Earhart, PhD; Lynne C. Huffman, MD; Casey E. Krueger, PhD; Ryan E. Lucash, PhD; Melinda S. Proud, RCP; Elizabeth N. Reichert, MA CCRC; Heather Taylor, PhD; Hali E. Weiss, MD; R. Jordan Williams, MD.

University of Alabama at Birmingham Health System and Children's Hospital of Alabama (UG1 HD34216) – Waldemar A. Carlo, MD; Namasivayam Ambalavanan, MD; Myriam Peralta-Carcelen, MD MPH; Fred J. Biasini, PhD; Monica V. Collins, RN BSN MaEd; Shirley S. Cosby, RN BSN; Kristy A. Domnanovich, PhD; Chantel J. Jno-Finn, PT DPT; Morissa Ladinsky, MD; Tara E. McNair, RN BSN; Vivien A. Phillips, RN BSN; Kimberlly Stringer, MD MPH; Sally Whitley, MA OTR-L FAOTA; Sheree York Chapman, PT DPT PCS.

University of California - Los Angeles, Mattel Children's Hospital, Santa Monica Hospital, Los Robles Hospital and Medical Center, and Olive View Medical Center (UG1 HD68270) – Uday Devaskar, MD; Meena Garg, MD; Isabell B. Purdy, PhD CPNP; Teresa Chanlaw, MPH; Rachel Geller, RN BSN.

University of Iowa, Mercy Medical Center, and Sanford Health (UG1 HD53109, UL1 TR442) – Edward F. Bell, MD; Tarah T. Colaizy, MD MPH; Jane E. Brumbaugh, MD; Heidi M. Harmon, MD; Karen J. Johnson, RN BSN; Mendi L. Schmelzel, RN MSN; Jacky R. Walker, RN; Claire A. Goeke, RN; Diane L. Eastman, RN CPNP MA; Michelle L. Baack, MD; Laurie A. Hogden, MD; Megan M. Henning, RN; Chelsey Elenkiwich, BSN RN; Megan Broadbent, RN BSN; Sarah Van Muyden, RN BSN; Dan L. Ellsbury, MD; Donia B. Campbell, MS ARNP NNP-BC; Tracy L. Tud, RN.

University of New Mexico Health Sciences Center (UG1 HD53089, UL1 TR41) – Janell Fuller, MD; Kristi L. Watterberg, MD; Robin K. Ohls, MD; Conra Backstrom Lacy, RN; Carol Hartenberger, BSN MPH; Sandra Sundquist Beauman, MSN RNC-NIC; Mary Ruffner Hanson, RN BSN; Jean R. Lowe, PhD; Elizabeth Kuan, RN BSN.

University of Pennsylvania, Hospital of the University of Pennsylvania, Pennsylvania Hospital, Children's Hospital of Philadelphia, and Virtua Voorhees Hospital (UG1 HD68244) – Sara B. DeMauro, MD MSCE; Eric C. Eichenwald, MD; Barbara Schmidt, MD MSc; Haresh Kirpalani, MB MSc; Karen M. Puopolo, MD PhD; Andrea F. Duncan, MD MSClinRes; Soraya Abbasi, MD; Sahar Z. Zangeneh, PhD; Aasma S. Chaudhary, BS RRT; Antoinette Mancini, RN BSN CCRC; Dara M. Cucinotta, RN; Judy C. Bernbaum, MD; Marsha Gerdes, PhD; Sarvin Ghavam, MD; Hallam Hurt, MD; Jonathan Snyder, RN BSN, Kristina Ziolkowski, CMA(AAMA) CCRP.

University of Rochester Medical Center, Golisano Children's Hospital, and the University of Buffalo Women's and Children's Hospital of Buffalo (UG1 HD68263, UL1 TR42) – Carl T. D'Angio, MD; Ronnie Guillet, MD PhD; Satyan Lakshminrusimha, MD; Anne Marie Reynolds, MD; Brenna Cavanaugh, PsyD BCBA-D; Gary J. Myers, MD; Ann Marie Scorsone, MS CCRC; Holly I.M. Wadkins; Michael G. Sacilowski, BS; Rosemary L. Jensen; Joan Merzbach, LMSW; William Zorn, PhD; Osman Farooq, MD; Stephanie Guilford, BS; Kelley Yost, PhD; Mary Rowan, RN; Diane Prinzing; Michelle Hartley-McAndrew, MD; Kyle Binion, BS; Constance Orme; Premini Sabaratnam, MPH; Alison Kent, BMBS FRACP MD; Rachel Jones; Elizabeth Boylin, BA; Daisy Rochez, BS MHA; Emily Li, BA; Jennifer Kachelmeyer, BS; Kimberly G. McKee, BS; Kelly R. Coleman, PsyD; Deanna Maffett, RN; Julieanne Hunn, BS; Melissa Bowman, RN; Ashley Williams, MS Ed; Cait Fallone, MA.

University of Texas Southwestern Medical Center, Parkland Health & Hospital System, and Children's Medical Center Dallas (UG1 HD40689) – Myra H. Wyckoff, MD; Pablo J. Sánchez, MD; Luc P. Brion, MD; Roy J. Heyne, MD; Diana M. Vasil, MSN BSN RNC-NIC; Maria M. De Leon, RN BSN; Frances Eubanks, RN BSN; E. Lara Pavageau, MD; Pollieanna Sepulveda, RN; Sally S. Adams, MS RN CPNP; Alicia Guzman; Elizabeth Heyne, MS MA PA-C, PsyD; Lizette E. Lee, RN; Rebecca McDougald, MSN APRN CPNP-PC/AC; Anna Puentez, MSN RN CPNP-PC; Azucena Vera, AS; Jillian Waterbury, DNP RN CPNP-PC; Cathy Twell Boatman, MS CIMI; Kristine Tolentino-Plata, MS PhD.

University of Utah Medical Center, Intermountain Medical Center, McKay-Dee Hospital, Utah Valley Hospital, and Primary Children's Medical Center (UG1 HD87226, UL1 TR105) – Robin K. Ohls, MD; Bradley A. Yoder, MD; Mariana Baserga, MD MSCI; Roger G. Faix, MD; Sarah Winter, MD; Stephen D. Minton, MD; Mark J. Sheffield, MD; Erick B. Gerday, MD; Laura Cole Bledsoe, RN; Kathleen Coleman, RN; Barbara L. Francom, BSN RN; Brixen A. Reich, RN MSN; Carrie A. Rau, RN BSN CCRC; Shawna Baker, RN; Jill Burnett, RNC BSN; Susan Christensen, RN; Sean D. Cunningham, PhD; Brandy Davis, RN BSN; Jennifer O. Elmont, RN BSN; Becky Hall, APRN; Erika R. Jensen, APRN; Jamie Jordan, RN BSN; Manndi C. Loertscher, BS CCRP; Trisha Marchant, RNC BSN; Earl Maxson, RN CCRN; Kandace M. McGrath, BS; Hena G. Mickelsen, BA; Galina Morshedzadeh, BSN APRN; D. Melody Parry, RN BSN; Susan T. Schaefer, RN BSN RRT; Kelly Stout, PhD; Ashley L. Stuart, PhD; Katherine Tice, RN BSN; Kimberlee Weaver-Lewis, RN MS; Kathryn D. Woodbury, RN BSN.

Wayne State University, Hutzel Women’s Hospital, Children’s Hospital of Michigan (UG1 HD21385) and University of Michigan Ann Arbor – Seetha Shankaran, MD; Beena G. Sood, MD MS; Athina Pappas, MD; Girija Natarajan, MD; Sanjay Chawla, MD; Monika Bajaj, MD; Prashant Agarwal, MD; Jeanette Prentice, MD; Melissa February, MD; Lilia De Jesus, MD; Gerry Muran, RN; Rebecca Bara, RN BSN; Kirsten Childs, RN BSN; Bogdan Panaitescu, MD; Eunice Hinz Woldt, RN MSN; Mary E. Johnson, RN BSN; Laura A. Goldston, MA; John Barks, MD; Stephanie A. Wiggins, MS; Mary K. Christensen, BA RRT; Diane F. White, RN MSN; Martha Carlson, MD.

Tables

Tables 1-5 are available in the Supplementary Files section.

References

1. Ford ND, Cox S, Ko JY, et al. Hypertensive Disorders in Pregnancy and Mortality at Delivery Hospitalization — United States, 2017–2019. *MMWR Morb Mortal Wkly Rep*. 2022;71(17). doi:10.15585/mmwr.mm7117a1

2. Conti-Ramsden F, Fleminger J, Lanoue J, Chappell LC, Battersby C, UK Neonatal Collaborative. The Contribution of Hypertensive Disorders of Pregnancy to Neonatal Unit Admissions and Iatrogenic Preterm Delivery at < 34+0 Weeks’ Gestation in the UK: A Population-Based Study Using the National Neonatal Research Database. *BJOG*. 2025;132(3):306-317. doi:10.1111/1471-0528.17976

3. Wang W, Xie X, Yuan T, et al. Epidemiological trends of maternal hypertensive disorders of pregnancy at the global, regional, and national levels: a population-based study. *BMC Pregnancy Childbirth*. 2021;21(1). doi:10.1186/s12884-021-03809-2

4. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. *The Lancet*. 2008;371(9606). doi:10.1016/S0140-6736(08)60074-4

5. Redman CWG, Cathrine Staff A. Fetal Growth Restriction and Hypertensive Diseases of Pregnancy. In: *Placental–Fetal Growth Restriction*. 2018. doi:10.1017/9781316181898.006

6. Srinivas SK, Edlow AG, Neff PM, Sammel MD, Andrela CM, Elovitz MA. Rethinking IUGR in preeclampsia: Dependent or independent of maternal hypertension? *Journal of Perinatology*. 2009;29(10). doi:10.1038/jp.2009.83

7. Yang L, Huang C, Zhao M, et al. Maternal hypertensive disorders during pregnancy and the risk of offspring diabetes mellitus in childhood, adolescence, and early adulthood: a nationwide population-based cohort study. *BMC Med*. 2023;21(1):59. doi:10.1186/s12916-023-02762-5

8. Kurbasic A, Fraser A, Mogren I, et al. Maternal Hypertensive Disorders of Pregnancy and Offspring Risk of Hypertension: A Population-Based Cohort and Sibling Study. *Am J Hypertens*. 2019;32(4):331-334. doi:10.1093/ajh/hpy176

9. Staff AC, Fjeldstad HE, Fosheim IK, et al. Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsia. *Am J Obstet Gynecol*. 2022;226(2). doi:10.1016/j.ajog.2020.09.026

10. Gumusoglu SB, Chilukuri ASS, Santillan DA, Santillan MK, Stevens HE. Neurodevelopmental Outcomes of Prenatal Preeclampsia Exposure. *Trends Neurosci*. 2020;43(4). doi:10.1016/j.tins.2020.02.003

11. Gumusoglu SB, Chilukuri ASS, Hing BWQ, et al. Altered offspring neurodevelopment in an arginine vasopressin preeclampsia model. *Transl Psychiatry*. 2021;11(1). doi:10.1038/s41398-021-01205-0

12. Scott H, Phillips TJ, Stuart GC, et al. Preeclamptic placentae release factors that damage neurons: Implications for foetal programming of disease. *Neuronal Signal*. 2018;2(4). doi:10.1042/NS20180139

13. Valencia-Narbona M, Torres E, Muñoz F, García T. Structural and functional cerebellar impairment in the progeny of preeclamptic rat mothers. *Neurosci Behav Physiol*. 2023;53(8). doi:10.1007/s11055-023-01503-8

14. Nakamura N, Ushida T, Onoda A, et al. Altered offspring neurodevelopment in an L-NAME-induced preeclampsia rat model. *Front Pediatr*. 2023;11. doi:10.3389/fped.2023.1168173

15. Barron A, McCarthy CM, O'Keeffe GW. Preeclampsia and Neurodevelopmental Outcomes: Potential Pathogenic Roles for Inflammation and Oxidative Stress? *Mol Neurobiol*. 2021;58(6):2734-

2756. doi:10.1007/s12035-021-02290-4

16. Xing QN, Liu YC, Xuan DS, Shang HL, Zhao X, Zhang XA. Diagnostic Value of Diffusion Tensor Imaging for Infants' Brain Development Retardation Caused by Pre-Eclampsia. *Contrast Media Mol Imaging*. 2021;2021. doi:10.1155/2021/5545178

17. Wang F, Yang YJ, Yang N, et al. Enhancing Oligodendrocyte Myelination Rescues Synaptic Loss and Improves Functional Recovery after Chronic Hypoxia. *Neuron*. 2018;99(4). doi:10.1016/j.neuron.2018.07.017

18. Rätsep MT, Paolozza A, Hickman AF, et al. Brain structural and vascular anatomy is altered in offspring of pre-eclamptic pregnancies: A pilot study. *American Journal of Neuroradiology*. 2016;37(5). doi:10.3174/ajnr.A4640

19. Maher GM, O'Keeffe GW, Kearney PM, et al. Association of hypertensive disorders of pregnancy with risk of neurodevelopmental disorders in offspring a systematic review and meta-analysis. *JAMA Psychiatry*. 2018;75(8). doi:10.1001/jamapsychiatry.2018.0854

20. Pinheiro T V., Brunetto S, Ramos JGL, Bernardi JR, Goldani MZ. Hypertensive disorders during pregnancy and health outcomes in the offspring: A systematic review. *J Dev Orig Health Dis*. 2016;7(4). doi:10.1017/S2040174416000209

21. Palatnik A, Mele L, Casey BM, et al. Association between Hypertensive Disorders of Pregnancy and Long-Term Neurodevelopmental Outcomes in the Offspring. *Am J Perinatol*. 2021;39(9). doi:10.1055/a-1692-0659

22. Noda M, Yoshida S, Mishina H, Matsubayashi K, Kawakami K. Association between maternal hypertensive disorders of pregnancy and child neurodevelopment at 3 years of age: A retrospective cohort study. *J Dev Orig Health Dis*. 2021;12(3). doi:10.1017/S2040174420000586

23. Chen KR, Yu T, Kang L, Lien YJ, Kuo PL. Childhood neurodevelopmental disorders and maternal hypertensive disorder of pregnancy. *Dev Med Child Neurol*. 2021;63(9):1107-1113. doi:10.1111/dmcn.14893

24. Sun BZ, Moster D, Harmon QE, Wilcox AJ. Association of Preeclampsia in Term Births With Neurodevelopmental Disorders in Offspring. *JAMA Psychiatry*. 2020;77(8):823-829. doi:10.1001/jamapsychiatry.2020.0306

25. Warshafsky C, Pudwell J, Walker M, Wen SW, Smith GN. Prospective assessment of neurodevelopment in children following a pregnancy complicated by severe pre-eclampsia. *BMJ Open*. 2016;6(7). doi:10.1136/bmjopen-2015-010884

26. Jain S, Barnes-Davis ME, Fu TT, et al. Hypertensive Disorders of Pregnancy and Risk of Early Brain Abnormalities on Magnetic Resonance Imaging at Term among Infants Born at ≤32 Weeks' Gestational

Age. *J Pediatr*. 2024;273:114133. doi:10.1016/j.jpeds.2024.114133

27. Abdelmageed WA, Lapointe A, Brown R, et al. Association between maternal hypertension and infant neurodevelopment in extremely preterm infants. . *Journal of Perinatology*. Published online January 29, 2024.

28. Jain S, Fu TT, Barnes-Davis ME, et al. Maternal Hypertension and Adverse Neurodevelopment in a Cohort of Preterm Infants. *JAMA Netw Open*. 2025;8(4):e257788. doi:10.1001/jamanetworkopen.2025.7788

29. Nakamura N, Ushida T, Nakatochi M, et al. Mortality and neurological outcomes in extremely and very preterm infants born to mothers with hypertensive disorders of pregnancy. *Sci Rep*. 2021;11(1). doi:10.1038/s41598-021-81292-7

30. Gemmell L, Martin L, Murphy KE, et al. Hypertensive disorders of pregnancy and outcomes of preterm infants of 24 to 28 weekś gestation. *Journal of Perinatology*. 2016;36(12). doi:10.1038/jp.2016.133

31. Manovitch Z, Morag I, Simchen MJ. Neurodevelopmental outcomes of preterm infants born to preeclamptic mothers – A case-control study. *European Journal of Obstetrics and Gynecology and Reproductive Biology*. 2022;270. doi:10.1016/j.ejogrb.2021.12.036

32. Morsing E, Maršál K, Ley D. Reduced Prevalence of Severe Intraventricular Hemorrhage in Very Preterm Infants Delivered after Maternal Preeclampsia. *Neonatology*. 2018;114(3). doi:10.1159/000489039

33. Sloane AJ, Flannery DD, Lafferty M, et al. Hypertensive disorders during pregnancy are associated with reduced severe intraventricular hemorrhage in very-low-birth-weight infants. *Journal of Perinatology*. 2019;39(8). doi:10.1038/s41372-019-0413-y

34. Check J, Shuster C, Hofheimer J, et al. Preeclampsia, Fetal Growth Restriction, and 24-Month Neurodevelopment in Very Preterm Infants. *JAMA Netw Open*. 2024;7(7):e2420382. doi:10.1001/jamanetworkopen.2024.20382

35. Matić M, Inati V, Abdel-Latif ME, Kent AL. Maternal hypertensive disorders are associated with increased use of respiratory support but not chronic lung disease or poorer neurodevelopmental outcomes in preterm neonates at <29 weeks of gestation. *J Paediatr Child Health*. 2017;53(4). doi:10.1111/jpc.13430

36. Kim HR, Lee BK. Outcomes of singleton preterm very low birth weight infants born to mothers with pregnancy-induced hypertension. *Sci Rep*. 2023;13(1). doi:10.1038/s41598-023-33206-y

37. Ananth C V., Schisterman EF. Confounding, causality, and confusion: the role of intermediate variables in interpreting observational studies in obstetrics. *Am J Obstet Gynecol*. 2017;217(2).

doi:10.1016/j.ajog.2017.04.016

38. Whitcomb BW, Schisterman EF, Perkins NJ, Platt RW. Quantification of collider-stratification bias and the birthweight paradox. *Paediatr Perinat Epidemiol*. 2009;23(5). doi:10.1111/j.1365-3016.2009.01053.x

39. Jain VG, Kline JE, He L, et al. Acute histologic chorioamnionitis independently and directly increases the risk for brain abnormalities seen on magnetic resonance imaging in very preterm infants. *Am J Obstet Gynecol*. 2022;227(4). doi:10.1016/j.ajog.2022.05.042

40. Jain VG, Parikh NA, Rysavy MA, et al. Funisitis increases the risk of death or cerebral palsy in extremely preterm infants. *Am J Obstet Gynecol*. 2025;233(3):197.e1-197.e13. doi:10.1016/j.ajog.2025.02.038

41. Greenwood C, Yudkin P, Sellers S, Impey L, Doyle P. Why is there a modifying effect of gestational age on risk factors for cerebral palsy? *Arch Dis Child Fetal Neonatal Ed*. 2005;90(2). doi:10.1136/adc.2004.052860

42. Regev RH, Arnon S, Litmanovitz I, et al. Outcome of singleton preterm small for gestational age infants born to mothers with pregnancy-induced hypertension. A population-based study. *J Matern Fetal Neonatal Med*. 2015;28(6):666-673. doi:10.3109/14767058.2014.928851

43. Greenland S, Pearce N. Statistical foundations for model-based adjustments. *Annu Rev Public Health*. 2015;36. doi:10.1146/annurev-publhealth-031914-122559

44. Benavente-Fernández I, Siddiqi A, Miller SP. Socioeconomic status and brain injury in children born preterm: modifying neurodevelopmental outcome. *Pediatr Res*. 2020;87(2):391-398. doi:10.1038/s41390-019-0646-7

45. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. *Obstetrics and Gynecology*. 2020;135(6). doi:10.1097/AOG.0000000000003891

46. Redline RW. Classification of placental lesions. *Am J Obstet Gynecol*. 2015;213(4). doi:10.1016/j.ajog.2015.05.056

47. Bayley N. Bayley Scales of Infant and Toddler Development, Third Edition. *PsycTESTS Dataset*. Preprint posted online October 8, 2012. doi:10.1037/t14978-000

48. Newman JE, Bann CM, Vohr BR, Dusick AM, Higgins RD. Improving the neonatal research network annual certification for neurologic examination of the 18-22 month child. *Journal of Pediatrics*. 2012;161(6). doi:10.1016/j.jpeds.2012.05.048

49. Battajon N, Bechini C, De Osti F, Galletti A, Frigo AC, Lago P. Neurodevelopmental outcomes of very low birth weight preterms in preschool childhood: a prospective cohort study. *Ital J Pediatr*. 2023;49(1).

doi:10.1186/s13052-023-01467-y

50. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. *Dev Med Child Neurol*. 1997;39(4):214-223. doi:10.1111/j.1469-8749.1997.tb07414.x

51. Adams-Chapman I, Heyne RJ, DeMauro SB, et al. Neurodevelopmental impairment among extremely preterm infants in the neonatal research network. *Pediatrics*. 2018;141(5). doi:10.1542/peds.2017-3091

52. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. *BMC Pediatr*. 2013;13(1). doi:10.1186/1471-2431-13-59


53. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. *The BMJ*. 2019;366. doi:10.1136/bmj.l2381

54. Ushida T, Kidokoro H, Nakamura N, et al. Impact of maternal hypertensive disorders of pregnancy on brain volumes at term-equivalent age in preterm infants: A voxel-based morphometry study. *Pregnancy Hypertens*. 2021;25. doi:10.1016/j.preghy.2021.06.003

55. MacKinnon DP, Krull JL, Lockwood CM. Equivalence of the mediation, confounding and suppression effect. *Prevention Science*. 2000;1(4). doi:10.1023/A:1026595011371

Figures

Figure 1. Directed Acyclic Graph Illustrating the Hypothesized Relationship Between Hypertensive Disorders of Pregnancy and Neurodevelopmental Outcomes in Extremely Preterm Infants




**Maternal Factors: Maternal age, maternal race, histologic chorioamnionitis, antenatal steroids, magnesium sulfate, birth hospital*

Figure 1

See image above for figure legend.

Figure 2. Participant flowchart outlining study population



** 2590 infants died before 22–26-month follow-up and were included only in analyses evaluating the composite outcome of death or neurodevelopmental impairment.*

Figure 2

See image above for figure legend.

Figure 3: Mediation Analysis of the Relationship Between Hypertensive Disorders of Pregnancy and Cognitive Outcomes at 2 Years Corrected Age




Figure 3

See image above for figure legend.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Table1new.docx
- Table2new.docx
- Table3AJOG.docx
- Table4AJOG.docx
- Table5AJOG.docx
- Supplementary1AJOG.docx